Patients with metastatic castration-resistant prostate cancer previously treated with external beam radiation therapy did not increase incidence of blood-related side effects with radium-223 compared ...

The administration of Pluvicto within six months of radium-223 treatment proved to be safe and efficacious in patients with metastatic castration-resistant prostate cancer, research showed. Patients ...

Researchers have found a way to predict which patients are likely to respond to radium-223, a standard treatment for advanced prostate cancer that has spread to the bones. By using an imaging ...

Adding radium-223 dichloride (Ra223) to metastasis-directed stereotactic ablative radiotherapy (SABR) did not improve progression-free survival compared with SABR alone in men with bone-only ...

Secondary outcomes by prior definitive treatment (tx) in patients (pts) with high-risk biochemically recurrent prostate cancer (hrBCR) treated with enzalutamide (enza) monotherapy (mono): EMBARK post ...

Final results for the key secondary endpoint of overall survival (OS) from the PEACE-3 trial will be presented by the European Organization for Research and Treatment of Cancer (EORTC) coalition as an ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The addition of six cycles of radium-223 to first-line ...

A phase 2 trial showed that olaparib plus radium 223 prolonged progression-free survival in a subset of patients with castration-resistant prostate cancer and bone metastases. Radiographic progression ...

Men with castration-resistant prostate cancer (CRPC) and asymptomatic or mildly symptomatic bone metastases lived significantly longer when they received enzalutamide (Xtandi) plus radium-223 (Ra-223, ...

Both are effective but work in slightly different ways: The newer of the two, lutetium-177, which was approved by the U.S. Food and Drug Administration (FDA) in 2022, can treat cancer that has ...

Researchers at the University of Sheffield have received new funding to investigate if radium-223 (Ra-223), currently used to treat bone metastases in prostate cancer, might also help in bone spread ...